Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, is pleased to announce the addition of four highly successful and accomplished biotech executives to the management team. These appointments come soon after the first closing of Antabio’s Series A financing round and notification that Antabio has been selected as one of 18 out of 368 international candidates for a CARB-X subsidy award of up to $8,9 million.
ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections
Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.
ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients
Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-X from a group of 368 applicants worldwide and is part of the first cohort that includes companies from Continental Europe.
Antabio’s CEO Marc Lemonnier has been elected at the Board of Directors of the BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) further to the alliance’s Extraordinary General Assembly held in Paris on 20 December 2016. The BEAM Alliance represents European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.
Antabio announced today that the company has received the BIOVISION Investment Conference 2016 Award in the biotech category. The BIOVISION Investor Conference was created to accelerate the fundraising process of Biotech, Medtech, e-health and environmental health start-ups by putting them in direct contact with potential business and development partners.
Antabio announced today that it has achieved two milestones in its antibacterial drug discovery collaborations with the Wellcome Trust. These results release a further €3.1 million from the Seeding Drug Discovery Awards received by Antabio. The first collaboration (“the MBLi program”) began in February 2013 when the Wellcome Trust awarded Antabio €4.7 million to fund the discovery of a novel, safe and efficacious inhibitor of bacterial metallo beta-lactamases (MBLs).
Dr. Marc Lemonnier, co-founder and CEO of Antabio, will participate in a BioPharma Dealmakers webcast, sponsored in part by Antabio, featuring five companies innovating antibiotic technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 8AM PST, 11AM EST, 4PM GMT, 5PM CET on March 9. The webcast will explore some of the technologies and companies tackling the emerging antibiotic resistance crisis.
Antabio signs the Industry call for new antimicrobial business models presented at the World Economic Forum, Davos
On January 21, 2016, the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched at an event at the World Economic Forum in Davos, Switzerland. This was drafted, agreed and signed by ANTABIO among 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries in 18 different countries.
ANTABIO receives €4 Million to develop new drugs to treat chronic infections in Cystic Fibrosis patients
Antabio SAS, a leading biopharmaceutical company in the field of antibacterial drug discovery, announced today that it has received a Wellcome Trust Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of chronic Pseudomonas infections in Cystic Fibrosis (CF) patients.
CF is the most common lethal, hereditary disease in Caucasian populations, affecting 1 in every 3,500 births in Europe with a current life expectancy of about 38 years among CF sufferers.
Antabio is now a member of the newly launched Alliance of Biotechs of Europe innovating in Anti-Microbial Resistance, called the BEAM Alliance. This group of European biotechnology companies is committed to tackling the unique challenges facing the industry in the antibacterial field and currently regroups 34 companies from 10 European countries.